Australia markets closed

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.6250-0.0100 (-0.28%)
As of 01:10PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 548.38M
Enterprise value 656.02M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.03
Price/book (mrq)12.60
Enterprise value/revenue 4.97
Enterprise value/EBITDA -1.55

Trading information

Stock price history

Beta (5Y monthly) 1.81
52-week change 3200.83%
S&P500 52-week change 323.23%
52-week high 33.9300
52-week low 30.5000
50-day moving average 33.0496
200-day moving average 32.0591

Share statistics

Avg vol (3-month) 32.11M
Avg vol (10-day) 31.65M
Shares outstanding 5150.65M
Implied shares outstanding 6153.14M
Float 8112.24M
% held by insiders 10.70%
% held by institutions 180.47%
Shares short (15 May 2024) 430.27M
Short ratio (15 May 2024) 412.27
Short % of float (15 May 2024) 426.03%
Short % of shares outstanding (15 May 2024) 420.09%
Shares short (prior month 15 Apr 2024) 425.43M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 313 Jan 2014

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin -61.28%
Operating margin (ttm)-13.84%

Management effectiveness

Return on assets (ttm)-18.45%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)132.1M
Revenue per share (ttm)0.90
Quarterly revenue growth (yoy)17.10%
Gross profit (ttm)N/A
EBITDA -61.88M
Net income avi to common (ttm)-80.95M
Diluted EPS (ttm)-0.5500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)71.52M
Total cash per share (mrq)0.47
Total debt (mrq)179.17M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.47
Book value per share (mrq)-0.22

Cash flow statement

Operating cash flow (ttm)-43.41M
Levered free cash flow (ttm)-11.77M